Location History:
- Hofheim, DE (2008 - 2021)
- Frankfurt-am-Main, DE (2023)
Company Filing History:
Years Active: 2008-2023
Title: **Marion Schneider: Innovator in Biotechnology**
Introduction
Marion Schneider is a notable inventor based in Hofheim, Germany, recognized for his contributions to the field of biotechnology. With a total of three patents, Schneider has made significant advancements in molecular biology, particularly in the development of novel cloning methods and therapeutic antibodies.
Latest Patents
One of Marion Schneider's latest patents is focused on intron-based universal cloning methods and compositions. This invention details a method for producing a fusion polynucleotide that encodes a polypeptide of interest. The process involves providing two polynucleotides, utilizing a type IIs restriction endonuclease and ligase to create a fusion polynucleotide that, when transcribed in a eukaryotic host cell, includes multiple introns.
Another significant patent pertains to antibody-like binding proteins that specifically bind to CD3 and CD123, along with their potential pharmaceutical applications. This invention addresses the use of anti-CD3 and anti-CD123 antibodies for cancer treatment, laying the groundwork for diagnostic tools that can enhance therapeutic strategies.
Career Highlights
Throughout his career, Marion Schneider has worked with prestigious companies, including Sanofi and Sanofi-Aventis. His experience with these industry leaders has allowed him to refine his innovative skills and contribute to groundbreaking research in biomedicine.
Collaborations
In his professional journey, Schneider has collaborated with several talented individuals, including Jana Albrecht and Cédric Barriere. These collaborations have fostered a creative environment that encourages the development of innovative solutions to complex biological problems.
Conclusion
Marion Schneider's inventive spirit and dedication to advancing biotechnology underscore his role as a prominent figure in the field. His patented innovations, particularly in cloning methods and antibody development, demonstrate his commitment to enhancing medical science and potentially transforming therapeutic practices.